Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0004867419831792 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Electroconvulsive therapy (ECT) is a well-established and effective treatment for severe depression and other conditions. Though ECT induces a generalized seizure, it is unclear why seizures are therapeutic. This study analyzed relationships between pre-treatment brain morphology, stimulation dose, and seizure duration to better understand ECT-induced seizures.
View Article and Find Full Text PDFEfficacy of Modified Electroconvulsive Therapy in Treatment-Resistant Schizophrenia.
Alpha Psychiatry
November 2024
Department of Psychiatry, Wuhan Wudong Hospital, Wuhan, China.
Objective: The aim of the study was to investigate the therapeutic effects of modified electroconvulsive therapy (MECT) in combination with risperidone tablets and psychotherapy in the treatment of patients with treatment-resistant schizophrenia (TRS).
Methods: Patients with TRS admitted to the psychiatric department of our hospital between January 2018 and December 2019 were selected as study participants. They were randomly divided into a control group and a study group, with the control group receiving risperidone tablets and psychotherapy, and the study group undergoing MECT as well as the control group treatment.
A Systematic Review of Knowledge, Attitude, and Perception Towards Electroconvulsive Therapy (ECT) in Africa.
Neuropsychiatr Dis Treat
January 2025
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Ontario, ON, Canada.
Background: Despite growing evidence showing ECT's efficacy and efficiency in the management of severe mental health conditions, the knowledge, attitude, and perceptions (KAP) towards ECT vary around the globe. However, KAP guarantees the extent to which ECT is accepted and administered efficiently. This review sheds light on the KAP toward ECT in Africa.
View Article and Find Full Text PDFThe Recognition and Management of Adverse Effects in Electroconvulsive Therapy: Findings From a Finnish Survey Study.
Brain Behav
January 2025
Turku University, Feculty of Medicine and Turku University Central Hospital, Division of Operative Services, Intensive Care and Acute Pain Management, Turku, Finland.
Aim: The aim of the study was to survey the observed incidence of adverse effects (AEs) related to electroconvulsive therapy (ECT) in Finnish neuromodulation units, as well as to explore what medical interventions are used to prevent and treat them in those units.
Methods: An electronic survey was conducted among Finnish neuromodulation units at the end of 2022. The survey included 35 questions related to AEs and their prevention and/or treatment in the responding units' ECT patient populations.
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.
Drugs Real World Outcomes
January 2025
Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Titusville, NJ, USA.
Introduction: Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes real-world mental health (MH)-related disability days and costs of patients with TRD initiated on esketamine nasal spray or conventional therapies in the USA.
Methods: Adults with TRD were selected from Merative™ MarketScan Commercial database (from January 2016 to January 2023) and classified into four cohorts (esketamine, ECT [electroconvulsive therapy], TMS [transcranial magnetic stimulation], and SGA [second-generation antipsychotics] augmentation) based on therapy initiated (index date) on/after 5 March 2019 (esketamine approval date for TRD).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!